ScreenerHero

ALEC Alector, Inc.

NAS · US · Healthcare · Biotechnology · alector.com
1.920USD+6.08%Mkt Cap: 214.38M $P/E: —

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant m…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap214.38M USD
Enterprise Value62.06M USD
Revenue (TTM)13.86M USD
Gross Profit-85.27M USD
Net Income (TTM)-142.93M USD
Revenue/Share0.13 USD
Last Price1.920 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.52
PEG—
EV/EBITDA-0.52
EV/Revenue4.48
P/S14.58
P/B-20.34
EPS (TTM)-1.09
EPS (Forward)-0.72
52W Range
1.09036% of range3.400
52W High3.400 USD
52W Low1.090 USD
Profitability
Gross Margin0.00%
Oper. Margin-734.73%
EBITDA Margin0.00%
Profit Margin-679.16%
ROE-466.34%
ROA-48.74%
Growth
Revenue Growth-57.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-184.03M USD
CapEx (TTM)41.00K USD
FCF Margin-773.66%
FCF Yield-50.03%
Net Debt-140.04M USD
Net Debt/EBITDA1.18
Balance Sheet
Debt/Equity1.18
Current Ratio5.26
Quick Ratio5.05
Book Value/Sh-0.09 USD
Cash/Share1.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.6 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.300 USD
Upside (mean)+71.9%
Target Range1.000 USD – 6.000 USD
1.000+71.9% to mean6.000
# Analysts5
Ownership
Shares Out.111.66M
Float84.94M
Insiders9.52%
Institutions93.29%
Short Interest
Short Ratio3.8d
Short % Float5.79%
Short % Out.5.47%
Shares Short6.10M
Short (prev mo.)5.90M
Technical
SMA 502.027 (-5.3%)
SMA 2001.995 (-3.8%)
Beta0.62
S&P 52W Chg16.45%
Avg Vol (30d)4.70M
Avg Vol (10d)9.89M
Technical Indicators
RSI (14)47.2
MACD-0.0572
MACD Signal-0.0371
MACD Hist.-0.0201
BB Upper2.340 USD
BB Middle2.002 USD
BB Lower1.663 USD
BB Width33.84%
ATR (14)0.2356 USD
Vol Ratio (20d)0.63x